Can a common drug shield children with sickle cell from stroke?

NCT ID NCT03948867

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This trial asks whether hydroxyurea, a daily oral medication, can reduce the risk of a first stroke in children with sickle cell anemia. Researchers will use transcranial Doppler (TCD) ultrasound to measure blood flow in the brain, a key indicator of stroke risk, in children aged 2 to 16 in Tanzania. Participants with elevated risk will receive hydroxyurea, and the study will track changes in TCD velocities over a year to see if the drug helps lower their stroke risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Hydroxyurea, a daily oral medication, plus transcranial Doppler (TCD) ultrasound screening to assess stroke risk.
What this could lead to
If effective, this could establish a practical strategy to prevent first strokes in children with sickle cell anemia in low-resource settings.
What could go wrong
The trial is early (Phase 2) and focuses on a biomarker (TCD velocity) rather than actual stroke events, so benefits may not translate directly. Hydroxyurea can cause side effects like bone marrow suppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL ANEMIA IN CHILDREN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bugando Medical Centre

    Mwanza, Tanzania

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.